Literature DB >> 26052967

Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score.

Elena Cerrillo1, Belén Beltrán, Salvador Pous, Ana Echarri, Jose Carlos Gallego, Marisa Iborra, Jose Pamies, Pilar Nos.   

Abstract

BACKGROUND: Magnetic resonance enterography (MRE) is an effective method of assessing small bowel Crohn's disease (CD). Fecal calprotectin (FC) correlates well with endoscopic disease activity. We aimed to evaluate the correlation between FC and disease activity according to MRE and surgical pathology in small bowel CD.
METHODS: One hundred twenty consecutive patients with ileal CD who underwent MRE assessment were included. Clinical data, C-reactive protein and FC, radiological and histological variables were obtained. Clinical activity was evaluated by the Harvey-Bradshaw Index and FC by enzyme-linked immunosorbent assay. MRE activity was assessed by means of the Magnetic Resonance Index of Activity score. Chiorean's score was used to grade pathological inflammation in surgical specimens.
RESULTS: Seventy-five patients (62.5%) were in clinical remission (Harvey-Bradshaw Index < 5) and 45 (37.5%) had active disease (Harvey-Bradshaw Index ≥ 5). The Magnetic Resonance Index of Activity score was significantly associated with FC levels (P < 0.01), with a moderate overall correlation (Spearman's r = 0.56, P < 0.001). FC reflected MRE inflammatory activity with an area under the receiver operating characteristic curve of 0.914 (confidence interval, 0.849-0.958; P < 0.001). A cutoff value of 166.50 μg/g had 90% sensitivity, 74% specificity, 89% positive predictive value, and 76% negative predictive value for diagnosis of inflammation. Twenty-eight of 120 patients were operated. Surgical pathology showed a good agreement with FC for moderate (P = 0.03) and severe (P = 0.01) Chiorean's index. No relationship was detected for C-reactive protein.
CONCLUSIONS: FC correlates with the degree of MRE inflammatory activity and with surgical pathology damage in ileal CD. Thus, FC could be a surrogate marker of disease control used to select patients for MRE assessment and therapeutic adjustment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26052967     DOI: 10.1097/MIB.0000000000000404

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  21 in total

Review 1.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

2.  Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease.

Authors:  James Turvill; Lisa Rook; Maxine Rawle; Gerry Robins; Simon Smale; Prashant Kant; Anne Phillips
Journal:  Frontline Gastroenterol       Date:  2017-01-30

3.  Fecal calprotectin predicts endoscopic activity and mucosal healing of small bowel Crohn's disease evaluated by double-balloon endoscopy.

Authors:  Wei Han; Juan Wu; Peipei Zhang; Naizhong Hu; Qiao Mei; Jing Hu
Journal:  Int J Colorectal Dis       Date:  2022-08-04       Impact factor: 2.796

4.  Endoscopic and Histological Findings Are Predicted by Fecal Calprotectin in Acute Intestinal Graft-Versus-Host-Disease.

Authors:  Birgit Adam; Michael Koldehoff; Markus Ditschkowski; Tanja Gromke; Michal Hlinka; Rudolf Trenschel; Lambros Kordeals; Nina K Steckel; Dietrich W Beelen; Tobias Liebregts
Journal:  Dig Dis Sci       Date:  2016-03-19       Impact factor: 3.199

5.  Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease.

Authors:  David J Gracie; Christopher J M Williams; Ruchit Sood; Saqib Mumtaz; M Hassan Bholah; P John Hamlin; Alexander C Ford
Journal:  Am J Gastroenterol       Date:  2016-03-22       Impact factor: 10.864

Review 6.  Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases?

Authors:  Parambir S Dulai; Siddharth Singh; Niels Vande Casteele; Brigid S Boland; Jesus Rivera-Nieves; Peter B Ernst; Lars Eckmann; Kim E Barrett; John T Chang; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2019-04-19       Impact factor: 13.576

7.  Inter- and intraobserver agreement in computed tomography enterography in inflammatory bowel disease.

Authors:  Natally Horvat; Camila Carlos Tavares; Adriana Ribas Andrade; Julia Campos Simões Cabral; Hilton Muniz Leao-Filho; Angela Hissae Motoyama Caiado; Serli Kiyomi Nakao Ueda; André Zonetti Arruda Leite; Aytan Miranda Sipahi; Manoel Souza Rocha
Journal:  World J Gastroenterol       Date:  2016-12-07       Impact factor: 5.742

8.  Faecal biomarkers for screening small bowel inflammation in patients with Crohn's disease: a prospective study.

Authors:  Takahiro Shimoyama; Takayuki Yamamoto; Satoru Umegae; Koichi Matsumoto
Journal:  Therap Adv Gastroenterol       Date:  2017-07-04       Impact factor: 4.409

9.  Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin.

Authors:  Yannick Derwa; Christopher J M Williams; Ruchit Sood; Saqib Mumtaz; M Hassan Bholah; Christian P Selinger; P John Hamlin; Alexander C Ford; David J Gracie
Journal:  Therap Adv Gastroenterol       Date:  2018-01-18       Impact factor: 4.409

10.  Levels of Faecal Calprotectin and Magnetic Resonance Enterocolonography Correlate with Severity of Small Bowel Crohn's Disease: A Retrospective Cohort Study.

Authors:  Lei Ye; Wei Cheng; Bi-Qin Chen; Xing Lan; Shao-Dong Wang; Xiao-Chen Wu; Wei Huang; Fang-Yu Wang
Journal:  Sci Rep       Date:  2017-05-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.